Preferred Label : Chimeric Antigen Receptor Therapy;
Origin ID : M000639995;
Related record
https://ansm.sante.fr/actualites/retour-dinformation-sur-le-prac-de-janvier-2024-8-11-janvier
2024
false
false
false
France
French
risk management
valproic acid
Male
Neurodevelopmental Disorders
Chimeric antigen receptor T-cell therapy
genetic therapy
Secondary Carcinoma
Chimeric Antigen Receptor Therapy
immunotherapy, adoptive
pharmacovigilance note
---
https://ansm.sante.fr/informations-de-securite/abecma-breyanzi-carvykti-kymriah-tecartus-et-yescarta-therapies-cellulaires-car-t-dirigees-contre-les-antigenes-cd19-ou-bcma-risque-de-tumeur-maligne-secondaire-issue-de-lymphocytes-t
2024
false
false
false
France
French
pharmacovigilance note
Secondary Malignant Neoplasm
Anti-CD19 CAR T Cells Preparation
Anti-BCMA CAR T Cells Preparation
Chimeric Antigen Receptor Therapy
lymphoma, T-Cell
continuity of patient care
hematologic neoplasms
leukemia, t-cell
Antineoplastic cell and gene therapy
---
https://ansm.sante.fr/actualites/retour-dinformation-sur-le-prac-de-juin-2024-10-13-juin
2024
false
false
false
France
French
pharmacovigilance note
risk assessment
risk
dipyrone
agranulocytosis
gene therapy
Chimeric Antigen Receptor T-cells
Antineoplastic Agents, Immunological
Therapy-Associated cancer
Chimeric Antigen Receptor Therapy
---
